{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:06:43Z","timestamp":1786993603746,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009663","name":"University Health Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009881","name":"Juvenile Diabetes Research Foundation Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007476","name":"Canadian Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.kint.2019.02.033","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T20:13:13Z","timestamp":1553199193000},"page":"489-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Analysis from the EMPA-REG OUTCOME\u00ae trial\u00a0indicates empagliflozin may assist in preventing\u00a0the\u00a0progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics"],"prefix":"10.1016","volume":"96","author":[{"given":"Gert J.","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Koitka-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"von Eynatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Zinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.02.033_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.02.033_bib2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.02.033_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.02.033_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.02.033_bib5","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.02.033_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1475-2840-13-102","article-title":"Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)","volume":"13","author":"Zinman","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.kint.2019.02.033_bib7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2019.02.033_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.02.033_bib9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.02.033_bib10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.02.033_bib11","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.kint.2019.02.033_bib12","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.02.033_bib13","doi-asserted-by":"crossref","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","article-title":"The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension","volume":"307","author":"Gembardt","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.02.033_bib14","doi-asserted-by":"crossref","unstructured":"Kidokoro K, Cherney DZI, Bozovic A, et\u00a0al. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in\u00a0vivo imaging [e-pub ahead of print]. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037418. Accessed February 19, 2019.","DOI":"10.1161\/CIRCULATIONAHA.118.037418"},{"key":"10.1016\/j.kint.2019.02.033_bib15","first-page":"F477","article-title":"Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations","volume":"265","author":"Anderson","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.kint.2019.02.033_bib16","first-page":"220","article-title":"Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the\u00a0former prevents late renal structural damage","volume":"2","author":"Perico","year":"1994","journal-title":"Exp Nephrol"},{"key":"10.1016\/j.kint.2019.02.033_bib17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1681\/ASN.2005080872","article-title":"Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes","volume":"17","author":"Sochett","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.033_bib18","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/00004872-199917121-00023","article-title":"Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats","volume":"17","author":"Fabris","year":"1999","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kint.2019.02.033_bib19","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2019.02.033_bib20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000229304","article-title":"Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2(Akita) mice","volume":"30","author":"Nasrallah","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2019.02.033_bib21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1172\/JCI10228","article-title":"Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes","volume":"107","author":"Komers","year":"2001","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2019.02.033_bib22","doi-asserted-by":"crossref","first-page":"27192","DOI":"10.1038\/srep27192","article-title":"Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure","volume":"6","author":"Ohno","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2019.02.033_bib23","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1093\/ndt\/gfn379","article-title":"Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption","volume":"23","author":"Chagnac","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.02.033_bib24","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clinthera.2014.12.018","article-title":"Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study","volume":"37","author":"Heise","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.kint.2019.02.033_bib25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.ki.5001633","article-title":"Unraveling the relationship between macula densa cell volume and luminal solute concentration\/osmolality","volume":"70","author":"Komlosi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.033_bib26","doi-asserted-by":"crossref","first-page":"C475","DOI":"10.1152\/ajpcell.00180.2008","article-title":"Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody","volume":"295","author":"Balen","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.kint.2019.02.033_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1681\/ASN.2009070759","article-title":"Macula densa sensing and signaling mechanisms of renin release","volume":"21","author":"Peti-Peterdi","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.033_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2019.02.033_bib29","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/HJH.0000000000000871","article-title":"Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome","volume":"34","author":"Rahman","year":"2016","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kint.2019.02.033_bib30","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.clinthera.2014.02.022","article-title":"Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"36","author":"Devineni","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.kint.2019.02.033_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1573402110666140131155331","article-title":"L-\/N-type calcium channel blockers and proteinuria","volume":"9","author":"Ando","year":"2013","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.kint.2019.02.033_bib32","first-page":"526","article-title":"Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus: analysis after switching from cilnidipine to benidipine","volume":"57","author":"Seino","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.kint.2019.02.033_bib33","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.amjhyper.2007.05.012","article-title":"Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria","volume":"20","author":"Fogari","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kint.2019.02.033_bib34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jdiacomp.2006.06.001","article-title":"Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy","volume":"21","author":"Fujisawa","year":"2007","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.kint.2019.02.033_bib35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/157339908786241151","article-title":"Insights into the regulation of renal hemodynamic function in diabetic mellitus","volume":"4","author":"Cherney","year":"2008","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.kint.2019.02.033_bib36","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2337\/db07-1230","article-title":"The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes","volume":"57","author":"Cherney","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2019.02.033_bib37","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.2337\/dc16-2200","article-title":"Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media","volume":"40","author":"Heyman","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2019.02.033_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","article-title":"Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia","volume":"41","author":"Szalat","year":"2018","journal-title":"Drug Safety"},{"key":"10.1016\/j.kint.2019.02.033_bib39","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2019.02.033_bib40","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/dom.12876","article-title":"Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus","volume":"19","author":"Desai","year":"2017","journal-title":"Diabetes Obes Metab"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819303175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819303175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:54:27Z","timestamp":1758761667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819303175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0085253819303175"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.02.033","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis from the EMPA-REG OUTCOME\u00ae trial\u00a0indicates empagliflozin may assist in preventing\u00a0the\u00a0progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.02.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}